FDA Approves Truxima (rituximab-abbs) as the First Biosimilar to Rituxan
Truxima, from Celltrion Inc., is also the third US biosimilar approved by the FDA in the past month Read More... Today, the U.S. Food and Drug Administration (FDA) approved Truxima (rituximab-abbs) injection as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL).
0 Comments
|
Categories |